Fisetin

Fisetin has been studied in 484 papers since 2006: 11 trials and 7 observational studies in people, 214 in animals, 115 in cells, 119 reviews; 83 in the past year. Its furthest trials in people are at phase 2. The newest story, Nov 11, 2026: “Fisetin pilot trial hints at benefits in lung disease”.

InterventionSenolyticsPhase 2

484 papers study it8 more mention it913 findingsUpdated

PubChemChEBIMeSH

Research on it is growing 34% faster than aging research as a whole: 50 papers in the latest year counted

More supplements

6 new papers in 30 daysSee all 428 papers on fisetin

At a glance

Fisetin extends lifespan in worm studies and a mouse study, with independent labs reproducing lifespan extension in yeast. However, a study in naturally aging female mice shows no clear survival or physical-function effect; human trials report lower C-reactive protein and CXCL12. Eleven registered trials concern aging; some papers have company-affiliated authors or declared company ties.

913 findings in 301 papers from 2007 to 2026, 21 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 170 independent labs in 32 countries; 24 trials, 13 about aging, 1 with no results posted.

“Nevertheless, in both OTT strata, fisetin treatment still markedly reduced the serum levels of MMP-2, MMP-9, and CRP.”
Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical TrialClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2019doi:10.1177/1076029619871359

34 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 170 independent labs in 32 countries
  • 34 findings against
  • 24 trials, 13 about aging, 1 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 25 of 819 findings with company ties
  • Human trial10
  • Humans6
  • Animals184
  • Model organisms8
  • Cells83
  • In silico7

7 studies gave fisetin to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on serious adverse eventsNo serious adverse events in either group; one mild diarrhea episode in each group

up: Increases DLCOcMedian change at days 90 and 180: +1.36 and +0.09 mL/min/mmHg with fisetin versus +0.13 and −1.84 with placebo

down: Decreases systolic blood pressureMedian change −15 mmHg with fisetin versus +7 mmHg with placebo at day 180

Randomized trial180 days10 peopleadultsCVID-associated GLILD; fisetin versus placeboAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, Nov 1, 2026

down: Decreases GLB1 expression

down: Decreases CDKN2A expression

down: Decreases MIF expression

Randomized trial45 days40 people>55 yearsMidlife adults; Older adults; Both dosing regimensPreprints.org, Jul 22, 2026

up: Improves endothelial function+41% flow-mediated dilation (3.9±0.4% to 5.5±0.5%)

down: Decreases mitoROS bioactivity~-10%

down: Decreases CXCL12-5%

Randomized trialintermittent (2, 3-day dosing periods separated by 14 days)22 peopleBoth71±1 yrsOlder adults; Postmenopausal women; ex vivo: human aortic endothelial cells exposed to 10% participant serumPhysiology, May 1, 2026

no change: Has no effect on telomere length

no change: Has no effect on adverse effects

Trialsix months10 peopleover 50 yearsMidlife adultsAlternative therapies in health and medicine, Sep 1, 2024

no change: Has no effect on gulf War Illness symptom severity

Trial10 months21 peoplemaleaged 46 to 57 (M = 49.76, SD = 2.76)Male veteransInternational journal of environmental research and public health, Mar 3, 2021

What did mouse lifespan tests of fisetin find?

NIA ITP

The NIA Interventions Testing Program ran 2 arms in 2018; the change in median lifespan ran from −5% to +7%.

What did other lifespan studies of fisetin find?

DrugAge

DrugAge records 3 results from 3 papers: 1 in D. melanogaster, 1 in mice and 1 in S. cerevisiae. Average lifespan is the mean or the median, as each paper reports it.

What did studies of fisetin find?

514

Studies of fisetin measured 514 outcomes; the most studied are apoptosis (37 studies), cellular senescence (28) and inflammation (24).

Apoptosis

upin human cells12upin reviews7downin rats6downin mice4+7

37 studies
  1. Fisetin induces apoptosis in senescent cells.

    “selectively activating pro-apoptotic pathways in senescent cells”

    Reviewin senescent cells

    Mechanistic Analysis of Fisetin in Liver Diseases and Its Potential Therapeutic Application in IFALD-A Review of In Vitro and In Vivo Studies

    Nutrients

  2. Fisetin induces apoptosis in experimentally induced lung cancer cells.

    “these roles include the promotion of apoptosis, inhibition of cell proliferation, migration, and invasion, as well as the regulation of autophagy”

    Reviewin experimentally induced lung cancer cells

    Exploring the therapeutic promise of fisetin: molecular mechanisms and clinical aspects in lung cancer

    Journal of complementary & integrative medicine

  3. Fisetin decreases apoptosis in chicken cells (H2O2-induced small white follicle).

    “fisetin significantly enhanced the anti-apoptotic capacity of SWF”

    CellsH2O2-induced small white folliclesmall white follicle

    Flavonoid Fisetin Alleviates Ovarian Aging of Laying Chickens by Enhancing Antioxidant Capacity and Glucose Metabolic Homeostasis

    Antioxidants (Basel, Switzerland)

  4. Fisetin decreases apoptosis in rats (methotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)).

    “The reduction in oxidative stress, inflammation, and apoptosis”

    Animalsmethotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)liver50 mg/kg/dayten daysmales

    Fisetin ameliorates methotrexate induced liver fibrosis

    European review for medical and pharmacological sciences

  5. Fisetin induces apoptosis in cells.

    “and induced apoptosis in vitro”

    Cellsself-assembled nanoparticles

    Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia

    International journal of pharmaceutics

  6. Fisetin decreases apoptosis in lactose-induced diarrheal rats.

    “Fisetin also restored the Na+/K+-ATPase level, apoptosis, protein content, and kidney architecture in diarrheal rats to be near the control group.”

    Animalsin lactose-induced diarrheal ratskidney50 mg/kg4 weeksmalesn = 6

    Fisetin Treats Kidney Oxidative Stress, Inflammation, and Apoptosis in Rat Diarrhea

    Frontiers in bioscience (Scholar edition)

  7. Fisetin induces apoptosis in senescence-induced HDFs.

    “this effect is attributable to cell death induction by caspases 3, 8, and 9-mediated endogenous and exogenous apoptosis”

    Cellsin senescence-induced HDFs

    Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis

    Biogerontology

  8. Fisetin induces apoptosis.

    “fisetin exhibits a range of biological effects, such as suppressing cell growth, triggering programmed cell death”

    Review

    Biological effects and mechanisms of fisetin in cancer: a promising anti-cancer agent

    European journal of medical research

  9. Fisetin induces apoptosis.

    “fisetin inhibits cancer cell growth through mechanisms such as cell cycle alteration, induction of apoptosis, and activation of the autophagy signaling pathway”

    Review

    Fisetin's Promising Antitumor Effects: Uncovering Mechanisms and Targeting for Future Therapies

    Global medical genetics

  10. Fisetin decreases apoptosis in mice (aging-induced).

    “Meanwhile, fisetin attenuated aging-induced spindle abnormalities, mitochondrial dysfunction, and apoptosis.”

    Animalsaging-inducedoocyte

    Fisetin Delays Postovulatory Oocyte Aging by Regulating Oxidative Stress and Mitochondrial Function through Sirt1 Pathway

    Molecules (Basel, Switzerland)

All 37

More on Apoptosis

Cellular senescence

downin mice10downin human cells7downin mouse cells2downin rat cells2+6

28 studies
  1. Fisetin decreases cellular senescence in humans (Cdkn1a -12%; Lmnb1 +16%).

    “expression of Cdkn1a was reduced (P< 0.05) by 12% and expression of Lmnb1 increased (P=0.06) by 16% in PBMCs collected after fisetin but not placebo”

    Human trialperipheral blood mononuclear cell2 mg/kg/day

    Intermittent fisetin treatment improves vascular endothelial function and suppresses cellular senescence in older adults: role of reduced mitochondria-related oxidative stress

    Physiology

  2. Fisetin decreases cellular senescence.

    “exerts senolytic activity by selectively eliminating senescent cells”

    Review

    Natural Bioactive Compounds Targeting Key Hallmarks of Aging: Functional Food Potential of Spermidine, Fisetin, Berberine, and Urolithin A

    Nutrients

  3. Fisetin decreases cellular senescence in mice (sustained release from DNA nanocage).

    “sustained Fisetin release eliminates senescent cells, fostering a pro-regenerative microenvironment”

    Animalssustained release from DNA nanocagenoncovalently encapsulated in DNA nanocageskin

    Light-responsive DNA cages sped early wound closure in aged mice

    Biomaterials

  4. Fisetin decreases cellular senescence in mice (doxorubicin-treated mice).

    “Fisetin mitigated excess vascular cell senescence and the SASP in young mice administered doxorubicin”

    Animalsdoxorubicin-treated miceintermittent oral supplementationvascular100 mg/kg/day

    Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress

    Aging cell

  5. Fisetin decreases cellular senescence (p16 and p21 expression as senescence markers in TMJOA models).

    “downregulated p16 and p21 as senescence markers”

    Animalsp16 and p21 expression as senescence markers in TMJOA modelsPLGA nanoparticles (FST-PNP)

    PLGA Nanoparticle-Mediated Sustained Release of Fisetin for Intra-Articular Therapy of Temporomandibular Joint Osteoarthritis

    International journal of molecular sciences

  6. Fisetin decreases cellular senescence in B cells.

    “fisetin was identified as an anti-senescence drug for mitigating B cell senescence and enhancing NICB efficacy.”

    Cellsin B cells

    Targeting senescent EGR1⁺ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma

    Cell reports. Medicine

  7. Fisetin decreases cellular senescence in mice.

    “reduced senescent cell amount in adipose tissue”

    Animalsadipose tissue

    Endothelial cell specific senescent cell clearance alleviates metabolic dysfunction in obese mice

    AHA Scientific Sessions 2025 abstract

  8. Fisetin decreases cellular senescence in human cells (oxalate-induced senescence in HK-2 cells).

    “the increase in RTEC senescence was reduced by fisetin treatment”

    Cellsoxalate-induced senescence in HK-2 cells

    Premature renal epithelial cell senescence promoted by LXN/Rps3/p53 signaling pathway activation increases calcium oxalate crystal deposition by altering macrophage polarization

    Frontiers in immunology

  9. Fisetin decreases cellular senescence in old mice, measured by skeletal muscle transcriptome.

    “including lower abundance of cellular senescence-related genes (e.g., Cdkn1a and Ddit4)”

    Animalsin old mice, measured by skeletal muscle transcriptomeskeletal muscle

    Intermittent Supplementation With Fisetin Improves Physical Function and Decreases Cellular Senescence in Skeletal Muscle With Aging: A Comparison to Genetic Clearance of Senescent Cells and Synthetic Senolytic Approaches

    Aging cell

  10. Fisetin decreases cellular senescence.

    “acting as a senolytic agent in multiple organ systems, in an hormetic fashion”

    Review

    Fisetin: hormesis accounts for many of its chemoprotective effects

    Biogerontology

All 28

More on Cellular senescence

Inflammation

downin reviews8downin rats6downin mice4downin human cells2+4

24 studies
  1. Fisetin decreases inflammation (reviewed preclinical findings).

    “Early findings in animal models and in human cell lines suggest that fisetin has the potential to mitigate age-related diseases by targeting chronic inflammation”

    Reviewreviewed preclinical findings

    Clinical Translation of Fisetin for Age-Related Diseases: Current Evidence and Future Opportunities

    Nutrients

  2. Fisetin decreases inflammation in vitro and in animal models (cited background).

    “Fisetin is a naturally occurring flavonoid with anti-inflammatory, antioxidant and senolytic effects in vitro and in animal models”

    Reviewin vitro and in animal models (cited background)

    Low-Dose Fisetin Supplementation and Its Association With Chronic Inflammation in Middle-Aged and Older Adults: Study Protocol for a Triple-Blind, Randomised, Placebo-Controlled Trial

    Basic & clinical pharmacology & toxicology

  3. Fisetin decreases inflammation.

    “exhibits diverse pharmacological activities including antioxidant, anti-inflammatory, anti-apoptotic, and anti-aging effects”

    Review

    Role of Fisetin in the Mammalian Reproductive System

    Veterinary sciences

  4. Fisetin inhibits inflammation in porcine alveolar macrophages (3D4/21).

    “reduced the expression of IL-6, TNF-α, and TLR4 in porcine alveolar macrophages (3D4/21)”

    Cellsin porcine alveolar macrophages (3D4/21)

    Effects of fisetin on virulence of Actinobacillus Pleuropneumoniae

    Microbial pathogenesis

  5. Fisetin decreases inflammation in silico (predicted by network pharmacology and molecular docking).

    “fisetin was identified as a promising compound with the potential to bind to the CD44 protein, mitigating the inflammatory response”

    In silicopredicted by network pharmacology and molecular docking

    Single-nucleus RNA sequencing and network pharmacology reveal the mediation of fisetin on neuroinflammation in Alzheimer's disease

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  6. Fisetin decreases inflammation.

    “The compound is also wellknown for its neurotrophic, anti-inflammatory, anti-carcinogenic, anti-diabetic, and other healthpromoting properties.”

    Review

    Fisetin from Dietary Supplement to a Drug Candidate: An Assessment of Potential

    Current pharmaceutical biotechnology

  7. Fisetin decreases inflammation in rats (methotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)).

    “The reduction in oxidative stress, inflammation, and apoptosis”

    Animalsmethotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)liver50 mg/kg/dayten daysmales

    Fisetin ameliorates methotrexate induced liver fibrosis

    European review for medical and pharmacological sciences

  8. Fisetin decreases inflammation in mice across various mouse models.

    “Fisetin consistently demonstrated marked anti-inflammatory actions across various models.”

    Animalsacross various mouse models

    Exploring the therapeutic potential of fisetin: a comprehensive study on its anti-nociceptive and anti-inflammatory effects

    European review for medical and pharmacological sciences

  9. Fisetin decreases inflammation in mice (adenine diet- and UUO-induced CKD models).

    “fisetin administration significantly ameliorated tubular injury, inflammation, and tubulointerstitial fibrosis in the two types of CKD mice”

    Animalsadenine diet- and UUO-induced CKD modelskidney50 or 100 mg·kg−1·d−13 weeks or 7 daysmales

    Fisetin ameliorates fibrotic kidney disease in mice via inhibiting ACSL4-mediated tubular ferroptosis

    Acta pharmacologica Sinica

  10. Fisetin decreases inflammation in rats (paracetamol-induced hepatotoxicity).

    “The TNF-α, NFκB and CYP2E1 gene expressions were significantly lower in both doses of the fisetin groups compared with the PARA group.”

    Animalsparacetamol-induced hepatotoxicityliver25 and 50 mg/kg

    Fisetin Attenuates Paracetamol-Induced Hepatotoxicity by Regulating CYP2E1 Enzyme

    Anais da Academia Brasileira de Ciencias

All 24

More on Inflammation

Oxidative stress and ROS signaling

downin mice7downin rats6downin reviews4downin human cells2+1

20 studies
  1. Fisetin decreases oxidative stress and ROS signaling.

    “exhibits diverse pharmacological activities including antioxidant, anti-inflammatory, anti-apoptotic, and anti-aging effects”

    Review

    Role of Fisetin in the Mammalian Reproductive System

    Veterinary sciences

  2. Fisetin decreases oxidative stress and ROS signaling in mice (hypercholesterolemic mouse model).

    “alleviates oxidative stress”

    Animalshypercholesterolemic mouse model

    Fisetin-loaded nanoparticles as a novel approach for cholesterol regulation in hypercholesterolemia: targeting the ASGR1-mediated mTORC1/AMPK pathway

    Journal of nanobiotechnology

  3. Fisetin decreases oxidative stress and ROS signaling in Aβ1−42-induced Alzheimer's disease model mice.

    “It also decreased oxidative and nitrosative stress, along with pro-inflammatory cytokine levels in the cortex, hippocampus and colon.”

    Animalsin Aβ1−42-induced Alzheimer's disease model micechitosan-coated nanoformulationcortex, hippocampus and colon5 mg/kg/day21 days

    Nanoformulated fisetin ameliorates Alzheimer's disease via reducing proinflammatory cytokines and activating the NRF2/HO-1 pathway

    Nanomedicine (London, England)

  4. Fisetin decreases oxidative stress and ROS signaling in ApoE-/- mice.

    “The level of reactive oxygen species and malondialdehyde declined”

    Animalsin ApoE-/- mice

    Fisetin Suppresses Atherosclerosis by Inhibiting Ferroptosis-Related Oxidative Stress in Apolipoprotein E Knockout Mice

    Pharmacology

  5. Fisetin decreases oxidative stress and ROS signaling in rats (methotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)).

    “The reduction in oxidative stress, inflammation, and apoptosis”

    Animalsmethotrexate-induced liver injury (20 mg/kg single intraperitoneal dose)liver50 mg/kg/dayten daysmales

    Fisetin ameliorates methotrexate induced liver fibrosis

    European review for medical and pharmacological sciences

  6. Fisetin decreases oxidative stress and ROS signaling in a DVT mouse model.

    “Fisetin exhibits potential therapeutic effects on DVT through its ability to attenuate inflammation and oxidative stress.”

    Animalsin a DVT mouse model

    Fisetin Alleviates Inflammation and Oxidative Stress in Deep Vein Thrombosis via MAPK and NRF2 Signaling Pathway

    International journal of molecular sciences

  7. Fisetin decreases oxidative stress and ROS signaling in MSG-induced toxicity.

    “it antagonized glutamate-induced oxidative stress by significantly lowering H2O2, NO, and relative NOX4 expression”

    Animalsin MSG-induced toxicitytestismales

    Fisetin ameliorates oxidative glutamate testicular toxicity in rats via central and peripheral mechanisms involving SIRT1 activation

    Redox report : communications in free radical research

  8. Fisetin decreases oxidative stress and ROS signaling.

    “The antioxidant properties of this flavonoid diminish oxidative stress, ROS production, neurotoxicity, neuro-inflammation, and neurological disorders.”

    Review

    The neuroprotective effects of fisetin, a natural flavonoid in neurodegenerative diseases: Focus on the role of oxidative stress

    Frontiers in pharmacology

  9. Fisetin decreases oxidative stress and ROS signaling.

    “reducing oxidative stress”

    Reviewmyocardium

    Recent advances in potential of Fisetin in the management of myocardial ischemia-reperfusion injury-A systematic review

    Phytomedicine : international journal of phytotherapy and phytopharmacology

  10. Fisetin decreases oxidative stress and ROS signaling in rats (bilateral renal ischemia-reperfusion injury).

    “At the cellular level, fisetin significantly reduced renal oxidative stress and augmented the antioxidant levels.”

    Animalsbilateral renal ischemia-reperfusion injurykidney20 mg/kg body weight24 h reperfusionmales

    Fisetin attenuates renal ischemia/reperfusion injury by improving mitochondrial quality, reducing apoptosis and oxidative stress

    Naunyn-Schmiedeberg's archives of pharmacology

All 20

More on Oxidative stress and ROS signaling

Reactive oxygen species

downin animals2downin human cells2downin mice2downin silico1+3

10 studies
  1. Fisetin decreases reactive oxygen species.

    “enhancement of SOD1 and CAT activity and reduction of ROS”

    Review

    Beneficial Effects of Fisetin, a Senotherapeutic Compound, in Women's Reproductive Health and Diseases: Evidence from In Vitro to Clinical Studies

    Nutrients

  2. Fisetin decreases reactive oxygen species in silico (compared with Trolox and ascorbate) (surpassing Trolox and ascorbate).

    “exhibiting significant potential against ⋅OOH, O2⋅−, and ⋅OH radicals, surpassing those of Trolox or ascorbate”

    In silicocompared with Trolox and ascorbate

    Fisetin as a Blueprint for Senotherapeutic Agents - Elucidating Geroprotective and Senolytic Properties with Molecular Modeling

    Chemistry (Weinheim an der Bergstrasse, Germany)

  3. Fisetin decreases reactive oxygen species in estropause mice.

    “Fisetin treatment reduced ROS levels in the hepatic tissue of estropause mice.”

    Animalsin estropause miceliverfemales

    Effect of senolytic drugs in young female mice chemically induced to estropause

    Life sciences

  4. Fisetin decreases reactive oxygen species in worms.

    “Fisetin reduced the cellular ROS levels”

    Model organisms

    Effects of Fisetin, a Plant-Derived Flavonoid, on Response to Oxidative Stress, Aging, and Age-Related Diseases in Caenorhabditis elegans

    Pharmaceuticals (Basel, Switzerland)

  5. Fisetin decreases reactive oxygen species in human cells (lipopolysaccharide-treated human microglia (HMC3)).

    “Fisetin, both incorporated and nonincorporated into polymersomes, reduces ROS and ERK1/2 phosphorylation in lipopolysaccharide-treated human microglia”

    Cellslipopolysaccharide-treated human microglia (HMC3)polymersome-encapsulated or non-incorporated

    Stimuli-Responsive Miktoarm Polymer-Based Formulations for Fisetin Delivery and Regulatory Effects in Hyperactive Human Microglia

    Macromolecular bioscience

  6. Fisetin decreases reactive oxygen species in human cells (PM2.5-exposed cells).

    “Fisetin strongly inhibited the production of reactive oxygen species (ROS)”

    CellsPM2.5-exposed cells

    Fisetin Protects HaCaT Human Keratinocytes from Fine Particulate Matter (PM2.5)-Induced Oxidative Stress and Apoptosis by Inhibiting the Endoplasmic Reticulum Stress Response

    Antioxidants (Basel, Switzerland)

  7. Fisetin decreases reactive oxygen species in rats (aging-induced increases in D-galactose-induced and naturally aged rats).

    “supplementation with fisetin suppresses aging-induced increases in the levels of reactive oxygen species, eryptosis, lipid peroxidation, and protein oxidation”

    Animalsaging-induced increases in D-galactose-induced and naturally aged ratserythrocytes15 mg/kg body mass6 weeks

    Fisetin, a potential caloric restriction mimetic, attenuates senescence biomarkers in rat erythrocytes

    Biochemistry and cell biology = Biochimie et biologie cellulaire

  8. Fisetin decreases reactive oxygen species in hypertrophic hearts and cardiomyocytes.

    “Reactive oxygen species (ROS) levels were markedly decreased by fisetin treatment in both hypertrophic hearts and cardiomyocytes”

    Animalsin hypertrophic hearts and cardiomyocytesheart

    Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress

    The Journal of nutritional biochemistry

  9. Fisetin decreases reactive oxygen species in mice (LPS-induced acute otitis media).

    “ROS production was significantly decreased in comparison to the LPS-treated group.”

    AnimalsLPS-induced acute otitis mediaten days

    Fisetin administration improves LPS-induced acute otitis media in mouse in vivo

    International journal of molecular medicine

  10. Fisetin decreases reactive oxygen species (hSOD1 mutant ALS models).

    “Fisetin treatment provided neuroprotection as demonstrated by an improved survival rate, attenuated motor impairment, reduced ROS damage”

    AnimalshSOD1 mutant ALS models

    Fisetin Exerts Antioxidant and Neuroprotective Effects in Multiple Mutant hSOD1 Models of Amyotrophic Lateral Sclerosis by Activating ERK

    Neuroscience

More on Reactive oxygen species

NF-κB signaling

downin mice3downin rats3downin mouse cells1downin rat cells1+1

9 studies
  1. Fisetin inhibits NF-κB signaling.

    “suppression of NF-κB signaling”

    Review

    Beneficial Effects of Fisetin, a Senotherapeutic Compound, in Women's Reproductive Health and Diseases: Evidence from In Vitro to Clinical Studies

    Nutrients

  2. Fisetin decreases NF-κB signaling in cisplatin-treated rats.

    “by elevating GPX4 levels and decreasing NF-kB expression”

    Animalsin cisplatin-treated rats10 mg/kgmales

    Fisetin mitigates cisplatin-induced peripheral neuropathy: a behavioral and immunohistochemical study

    Molecular biology reports

  3. Fisetin inhibits NF-κB signaling in mouse cells (together with MAPK signaling inhibition).

    “This effect was dependent on the inhibition of the NF-κB and MAPK signaling pathways.”

    Cellstogether with MAPK signaling inhibition

    Alleviation of obesity cardiomyopathy by Fisetin through the inhibition of NF-κB/MAPK signaling

    International immunopharmacology

  4. Fisetin inhibits NF-κB signaling in rats (ischemia/reperfusion injury model).

    “inhibited expression of NF-κB”

    Animalsischemia/reperfusion injury modelmyocardium

    Protective effects of fisetin against myocardial ischemia/reperfusion injury

    Experimental and therapeutic medicine

  5. Fisetin inhibits NF-κB signaling in rats (post-MI).

    “fisetin markedly increased phosphorylated AMPK (p-AMPK) levels and suppressed NF-κB p65, p38MAPK, and smad3 phosphorylation in the LA post-MI.”

    Animalspost-MIleft atrium

    Fisetin Alleviates Atrial Inflammation, Remodeling, and Vulnerability to Atrial Fibrillation after Myocardial Infarction

    International heart journal

  6. Fisetin inhibits NF-κB signaling in high-fructose diet-fed mice.

    “fisetin significantly suppressed the nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) pathway”

    Animalsin high-fructose diet-fed mice

    Fisetin Attenuates Metabolic Dysfunction in Mice Challenged with a High-Fructose Diet

    Journal of agricultural and food chemistry

  7. Fisetin inhibits NF-κB signaling in mice (LPS-induced acute otitis media).

    “accompanied with TLR4/NF-κB inactivation”

    AnimalsLPS-induced acute otitis mediaten days

    Fisetin administration improves LPS-induced acute otitis media in mouse in vivo

    International journal of molecular medicine

  8. Fisetin inhibits NF-κB signaling in mice (OVA-induced asthma model).

    “fisetin-treated mice after OVA induction inhibited activation of MyD88 and NF-κB signaling pathways”

    AnimalsOVA-induced asthma model40 and 50 mg/kg

    Fisetin-treatment alleviates airway inflammation through inhbition of MyD88/NF-κB signaling pathway

    International journal of molecular medicine

  9. Fisetin inhibits NF-κB signaling in hypoxia/reoxygenation-induced injury.

    “FIS inhibited the increasing expression levels of TLR4 and NF-κBp65 induced by H/R.”

    Cellsin hypoxia/reoxygenation-induced injuryBRL-3A cells

    Fisetin alleviates hypoxia/reoxygenation injury in rat hepatocytes via modulation of TLR4/NF-κB signaling pathway

    Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology

More on NF-κB signaling

Senescence-associated secretory phenotype (SASP)

downin mice3downin human cells2downin humans2downin cells1

8 studies
  1. Fisetin decreases senescence-associated secretory phenotype (SASP) in mice (doxorubicin-treated mice).

    “Fisetin mitigated excess vascular cell senescence and the SASP in young mice administered doxorubicin”

    Animalsdoxorubicin-treated miceintermittent oral supplementation100 mg/kg/day

    Fisetin Supplementation Attenuates Premature Vascular Aging Induced by Doxorubicin via Suppression of Cellular Senescence and Mitochondrial Oxidative Stress

    Aging cell

  2. Fisetin decreases senescence-associated secretory phenotype (SASP) in humans (preliminary human studies).

    “Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP)”

    Reviewpreliminary human studieshigh-dose

    Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline

    Naunyn-Schmiedeberg's archives of pharmacology

  3. Fisetin decreases senescence-associated secretory phenotype (SASP) in human cells (doxorubicin-induced senescence).

    “a significant reduction in IL-6 and IL-8 secretion in senescent cells”

    Cellsdoxorubicin-induced senescenceliposome-encapsulated

    Targeting Cellular Senescence with Liposome-Encapsulated Fisetin: Evidence of Senomorphic Effect

    International journal of molecular sciences

  4. Fisetin decreases senescence-associated secretory phenotype (SASP) in CPCs from osteoarthritic cartilage.

    “Additionally, SASP-related genes and proteins (MMP-9, MMP13) and inflammatory mediators (IL-1β, TGF-β, and IL-6) were downregulated.”

    Cellsin CPCs from osteoarthritic cartilage

    Fisetin and resveratrol exhibit senotherapeutic effects and suppress cellular senescence in osteoarthritic cartilage-derived chondrogenic progenitor cells

    European journal of pharmacology

  5. Fisetin decreases senescence-associated secretory phenotype (SASP) in human skin grafts in nude mice.

    “decreased senescence-associated secretory phenotypes (SASP), including matrix metalloproteinases and interleukins”

    Animalsin human skin grafts in nude miceskin30 d

    Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis

    Biogerontology

  6. Fisetin decreases senescence-associated secretory phenotype (SASP) in mice.

    “Fisetin treated male mice had reduced SASP, enhanced glucose and energy metabolism, improved cognitive performance”

    Animals100 mg/kgfrom 4 to 13 months of agemales

    Sexual dimorphic metabolic and cognitive responses of C57BL/6 mice to Fisetin or Dasatinib and quercetin cocktail oral treatment

    GeroScience

  7. Fisetin decreases senescence-associated secretory phenotype (SASP) in MRL/lpr SLE model mice.

    “transcription of several senescence and senescence-associated secretory phenotype (SASP) factors in the hippocampal region also decreased after fisetin treatment in the MRL/lpr mice”

    Animalsin MRL/lpr SLE model micehippocampus

    Accumulation of Senescent Neural Cells in Murine Lupus With Depression-Like Behavior

    Frontiers in immunology

  8. Fisetin decreases senescence-associated secretory phenotype (SASP) in cells.

    “FIS administration significantly inhibited the senescence of alveolar epithelial cells and senescence-associated secretory phenotype”

    Cells

    Fisetin Alleviated Bleomycin-Induced Pulmonary Fibrosis Partly by Rescuing Alveolar Epithelial Cells From Senescence

    Frontiers in pharmacology

More on Senescence-associated secretory phenotype (SASP)

Autophagy

upin mice2upin rats2upin cells1upin human cells1+2

8 studies
  1. Fisetin activates autophagy in SOD1G93A-expressing NSC34 cells.

    “Fisetin treatment (1-10 μ M) dose-dependently reduced both soluble and aggregated SOD1G93A protein, concomitantly with restored autophagic flux.”

    Cellsin SOD1G93A-expressing NSC34 cells1-10 μM

    Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation

    Journal of molecular neuroscience : MN

  2. Fisetin increases autophagy in rats after spinal cord injury.

    “Fisetin significantly augmented autophagic activity in injured spinal cord tissue”

    Animalsafter spinal cord injuryspinal cord

    Fisetin orchestrates neuroinflammation resolution and facilitates spinal cord injury recovery through enhanced autophagy in pro-inflammatory glial cells

    International immunopharmacology

  3. Fisetin increases autophagy in human cells.

    “increased the expression of autophagy markers LC3A/B and Atg5 in HEKa cells”

    Cells

    Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation

    Frontiers in immunology

  4. Fisetin activates autophagy in mice (SIRT1-mediated).

    “fisetin promoted SIRT1-mediated autophagy and inhibited Sphk1-mediated endoplasmic reticulum stress”

    AnimalsSIRT1-mediated

    Fisetin Ameliorates Alcohol-Induced Liver Injury through Regulating SIRT1 and SphK1 Pathway

    The American journal of Chinese medicine

  5. Fisetin activates autophagy in mouse cells.

    “activated autophagosome formation”

    Cells

    Fisetin Attenuates Diabetic Nephropathy-Induced Podocyte Injury by Inhibiting NLRP3 Inflammasome

    Frontiers in pharmacology

  6. Fisetin inhibits autophagy in human cells (HepG2 cells treated for 24 h).

    “Cyto-ID staining followed by flow cytometry showed that fisetin decreased autophagic flux formation in a dose-dependent manner.”

    CellsHepG2 cells treated for 24 h25, 50, and 100 μM24 h

    Fisetin Inhibits Autophagy in HepG2 Cells via PI3K/Akt/mTOR and AMPK Pathway

    Nutrition and cancer

  7. Fisetin activates autophagy in mice (APAP-induced injury, in vivo and in vitro).

    “FST significantly promoted APAP-induced autophagy and inhibited inflammasome activation both in vivo and in vitro”

    AnimalsAPAP-induced injury, in vivo and in vitroliver

    Fisetin Prevents Acetaminophen-Induced Liver Injury by Promoting Autophagy

    Frontiers in pharmacology

  8. Fisetin increases autophagy in aging rat brain.

    “fisetin up-regulated the expression of autophagy genes (Atg-3 and Beclin-1)”

    Animalsin aging rat brainbrain

    Fisetin as a caloric restriction mimetic protects rat brain against aging induced oxidative stress, apoptosis and neurodegeneration

    Life sciences

More on Autophagy

Lifespan

upin mice3upin worms3no changein mice1upin reviews1

8 studies
  1. Fisetin improves lifespan in mice (APP-infected mice).

    “improved the survival rate of APP-infected mice”

    AnimalsAPP-infected mice

    Effects of fisetin on virulence of Actinobacillus Pleuropneumoniae

    Microbial pathogenesis

  2. Fisetin extends lifespan in worms.

    “five compounds (all-trans retinoic acid, berberine, fisetin, propranolol, and ritonavir) extended lifespan in Caenorhabditis elegans.”

    Model organisms

    Computer prediction and genetic analysis identifies retinoic acid modulation as a driver of conserved longevity pathways in genetically-diverse Caenorhabditis nematodes

    eLifePreprint

  3. Fisetin extends lifespan in a hypomorphic mouse model of recessive dystrophic epidermolysis bullosa.

    “we demonstrate fisetin’s ability to increase survival and reduce senescent cell burden in a hypomorphic mouse model of RDEB”

    Animalsin a hypomorphic mouse model of recessive dystrophic epidermolysis bullosa

    Fisetin extends lifespan in a murine model of recessive dystrophic epidermolysis bullosa

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  4. Fisetin showed no clear effect on lifespan in mice (at the dose and method of administration tested).

    “None of these increased lifespan significantly at the dose and method of administration tested in either sex.”

    Animalsat the dose and method of administration testedmale and females

    Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used

    GeroScience

  5. Fisetin extends lifespan in worms.

    “Both the mean and maximum lifespans were significantly extended by fisetin”

    Model organisms

    Effects of Fisetin, a Plant-Derived Flavonoid, on Response to Oxidative Stress, Aging, and Age-Related Diseases in Caenorhabditis elegans

    Pharmaceuticals (Basel, Switzerland)

  6. Fisetin extends lifespan.

    “fisetin) has been reported as a potent senotherapeutic capable of extending lifespan”

    Review

    Fisetin as a Senotherapeutic Agent: Biopharmaceutical Properties and Crosstalk between Cell Senescence and Neuroprotection

    Molecules (Basel, Switzerland)

  7. Fisetin extends lifespan in worms.

    “effectively increased C. elegans lifespan and fertility”

    Model organisms

    Fisetin regulates gut microbiota to decrease CCR9⁺/CXCR3⁺/CD4⁺ T-lymphocyte count and IL-12 secretion to alleviate premature ovarian failure in mice

    American journal of translational research

  8. Fisetin extends lifespan in mice (late-life administration to wild-type mice).

    “Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan.”

    Animalslate-life administration to wild-type mice

    Fisetin is a senotherapeutic that extends health and lifespan

    EBioMedicine

Cell proliferation

downin human cells7

7 studies
  1. Fisetin decreases cell proliferation in colon cancer cell lines.

    “We identified three phytochemicals (fisetin, glabridin, and silibinin) that suppressed cell proliferation and were associated with changes in cancer-related miRNA expression in colon cancer cells.”

    Cellsin colon cancer cell lines

    Discovering Anticancer Effects of Phytochemicals on MicroRNA in the Context of Data Mining

    Nutrients

  2. Fisetin decreases cell proliferation in human cells (HeLa cells).

    “fisetin deters human cervical cancer cell proliferation”

    CellsHeLa cells

    Fisetin Deters Cell Proliferation, Induces Apoptosis, Alleviates Oxidative Stress and Inflammation in Human Cancer Cells, HeLa

    International journal of molecular sciences

  3. Fisetin decreases cell proliferation in human cells.

    “We found that fisetin inhibited proliferation, migration, and osteogenic differentiation of MSCs as well as human SaOs-2 cells.”

    Cells

    Fisetin Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells via the Inhibition of YAP

    Antioxidants (Basel, Switzerland)

  4. Fisetin inhibits cell proliferation in human cells.

    “We found that fisetin inhibited cell proliferation and induced DNA damage and S-phase arrest in PDAC.”

    Cells

    Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP/KDM4A-dependent histone H3K36 demethylation

    Cell death & disease

  5. Fisetin decreases cell proliferation in OSCC cells in vitro.

    “Fisetin treatment significantly inhibited proliferation and promoted apoptosis by repressing PAK4 expression.”

    Cellsin OSCC cells in vitro

    Fisetin Modulates Human Oral Squamous Cell Carcinoma Proliferation by Blocking PAK4 Signaling Pathways

    Drug design, development and therapy

  6. Fisetin decreases cell proliferation in human cells (T98G glioma cells, MTT assay; IC50 93 μM at 24 h and 75 μM at 48 h) (IC50 93 μM at 24 h and 75 μM at 48 h in T98G cells).

    “investigated the antiproliferative effects of 1-500 μM fisetin in T98G and BEAS-2B cells by MTT assay”

    CellsT98G glioma cells, MTT assay; IC50 93 μM at 24 h and 75 μM at 48 h1-500 μM24 and 48 h

    Fisetin effects on cell proliferation and apoptosis in glioma cells

    Zeitschrift fur Naturforschung. C, Journal of biosciences

  7. Fisetin decreases cell proliferation in human cells (SGC7901 cells).

    “Treatment of SGC7901 cells with various concentrations (1, 5, 10, 15 and 20 μM) of fisetin for 48 h resulted in a concentration dependent reduction in proliferation.”

    CellsSGC7901 cells1–20 μM48 h

    Fisetin inhibits the proliferation of gastric cancer cells and induces apoptosis through suppression of ERK 1/2 activation

    Oncology letters

Endothelial function

upin humans1upin mice1

2 studies
  1. Fisetin improves endothelial function in humans (+41% flow-mediated dilation (3.9±0.4% to 5.5±0.5%)).

    “FMDBA was improved by 41% with fisetin (pre: 3.9±0.4%, post: 5.5±0.5%, P< 0.0001), but unchanged with placebo”

    Human trialBioFisetinbrachial artery2 mg/kg/dayintermittent (2, 3-day dosing periods separated by 14 days)n = 22

    Intermittent fisetin treatment improves vascular endothelial function and suppresses cellular senescence in older adults: role of reduced mitochondria-related oxidative stress

    Physiology

  2. Fisetin improves endothelial function in mice (old mice after oral intermittent supplementation).

    “Old fisetin-supplemented mice had higher endothelial function.”

    Animalsold mice after oral intermittent supplementationendothelium1 week on, 2 weeks off, 1 week on

    Intermittent supplementation with fisetin improves arterial function in old mice by decreasing cellular senescence

    Aging cell

C-reactive protein

downin humans2

2 studies
  1. Fisetin decreases C-reactive protein in humans.

    “Nevertheless, in both OTT strata, fisetin treatment still markedly reduced the serum levels of MMP-2, MMP-9, and CRP.”

    Human trial7 daysn = 192

    Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

  2. Fisetin decreases C-reactive protein in humans within-group change in fisetin group (p < 0.01 within fisetin group).

    “After the intervention, the plasma levels of IL-8 and hs-CRP reduced significantly in the fisetin group (p < 0.04 and p < 0.01, respectively).”

    Human trialwithin-group change in fisetin group100 mgseven consecutive weeksn = 37

    Effect of fisetin supplementation on inflammatory factors and matrix metalloproteinase enzymes in colorectal cancer patients

    Food & function

More on C-reactive protein

Gulf War Illness symptom severity

no changein humans1

1 study
  1. Fisetin showed no clear effect on gulf War Illness symptom severity in humans (versus placebo, at lower and higher dosages) (p = 0.504 (lower dose), p = 0.616 (higher dose)).

    “Similarly, fisetin did not reduce symptom severity at either the lower (p = 0.504) or higher (p = 0.616) dosages.”

    Human trialversus placebo, at lower and higher dosagesfrom Rhus succedanea1 month per dose phasemalesn = 21

    A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea)

    International journal of environmental research and public health

  2. Fisetin showed no clear effect on gulf War Illness symptom severity in humans.

    “The LMM did not show a significant main effect for condition [F (3, 559) = 0.175, p = 0.913).”

    Human trial10 monthsn = 10

    A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Resveratrol (Polygonum cuspidatum), Luteolin, and Fisetin (Rhus succedanea)

    International journal of environmental research and public health

NIHSS

no changein humans1upin humans1

1 study
  1. Fisetin showed no clear effect on NIHSS in humans (normal OTT (0 to 3 hours)).

    “One day after the initiation of rt-PA treatment, in the 0- to 3-hour OTT strata, distribution of NIHSS scores of patients receiving simultaneous fisetin treatment was statistically indistinguishable from that of patients receiving placebo (; 0- to 3-hour OTT/fisetin vs 0- to 3-hour OTT/placebo).”

    Human trialnormal OTT (0 to 3 hours)7 daysn = 130

    Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

  2. Fisetin improves NIHSS in humans (delayed OTT (3 to 5 hours)).

    “However, within this 3- to 5-hour OTT strata, patients receiving fisetin exhibited great improvement as compared to those given placebo (; 3- to 5-hour OTT/fisetin vs 3- to 5-hour OTT/placebo).”

    Human trialdelayed OTT (3 to 5 hours)7 daysn = 62

    Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial

    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Frailty score

no changein humans1

1 study
  1. Fisetin showed no clear effect on frailty score in humans (CVID-associated GLILD; within fisetin group) (Median score unchanged with fisetin; increased by 2 points with placebo).

    “Median frailty score remained unchanged with fisetin but increased by 2 points with placebo.”

    Human trialCVID-associated GLILD; within fisetin group20 mg/kg on days 0, 1, 28, and 29n = 10

    Fisetin pilot trial hints at benefits in lung disease

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

All 514

What is fisetin linked with?

15

Studies link fisetin with 15 measures, among them senescence and SASP biomarkers, cancer-related microRNA expression and ATG101 binding stability.

Senescence and SASP biomarkers

mixedin humans1

1 study
  1. Fisetin is associated with senescence and SASP biomarkers in humans.

    “potential of fisetin and quercetin to modulate senescence and SASP biomarkers in animal models of aging and progeria, as well as in interventional studies involving human subjects”

    Review

    Exploring the Senotherapeutic Potential of Polyphenols in Aging and Disease: A Literature Review

    International journal of molecular sciences

More on Senescence and SASP biomarkers

Cancer-related microRNA expression

mixedin human cells1

1 study
  1. Fisetin is associated with cancer-related microRNA expression in colon cancer cell lines.

    “We identified three phytochemicals (fisetin, glabridin, and silibinin) that suppressed cell proliferation and were associated with changes in cancer-related miRNA expression in colon cancer cells.”

    Cellsin colon cancer cell lines

    Discovering Anticancer Effects of Phytochemicals on MicroRNA in the Context of Data Mining

    Nutrients

More on Cancer-related microRNA expression

ATG101 binding stability

upin silico1

1 study
  1. Fisetin is associated with ATG101 binding stability in silico (compared with chlorogenic acid; molecular docking and molecular dynamics simulation).

    “Our results indicated that fisetin forms a more stable complex with ATG101 compared to CGA.”

    In silicocompared with chlorogenic acid; molecular docking and molecular dynamics simulation

    Caloric restriction mimetics chlorogenic acid and fisetin as potential autophagy inducers targeting ATG101

    Biochemistry and biophysics reports

Therapeutic index

upin mice1

1 study
  1. Fisetin is associated with therapeutic index in mice (Parkinson's disease; compared with other screened Chinese medicines) (Best therapeutic index among 10 Chinese medicines).

    “identifying fisetin as having the best therapeutic index among 10 Chinese medicines.”

    AnimalsParkinson's disease; compared with other screened Chinese medicinesbrain

    Screening Anti-Parkinson's Disease Drugs in Living Mouse Brains via a Peroxynitrite-Activated Fluorescent Probe

    Chemical & biomedical imaging

HTR3A

upin silico1

1 study
  1. Fisetin is associated with HTR3A in silico (molecular docking simulation) (strong H-bond interactions with Trp156 residue).

    “fisetin interacts with the orthosteric site of the 5-HT3A receptor with strong H-bond interactions with the Trp156 residue”

    In silicomolecular docking simulation

    Anxiolytic and Anticonvulsant Effects of Fisetin Isolated from Bauhinia pentandra on Adult Zebrafish (Danio rerio)

    Chemistry & biodiversity

More on HTR3A

Senescence-related serum biomarkers

downin humans1

1 study
  1. Fisetin is associated with senescence-related serum biomarkers in humans (small subgroup of participants taking fisetin).

    “The percent of C12FDG+ PBMCs and age-related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin.”

    Humanssmall subgroup of participants taking fisetinserum

    Clinical validation of C₁₂FDG as a marker associated with senescence and osteoarthritic phenotypes

    Aging cell

More on Senescence-related serum biomarkers

C12FDG-positive PBMC percentage

downin humans1

1 study
  1. Fisetin is associated with C12FDG-positive PBMC percentage in humans (small subgroup of participants taking fisetin).

    “The percent of C12FDG+ PBMCs and age-related serum biomarkers were decreased in a small subgroup of study participants taking the senolytic drug fisetin.”

    Humanssmall subgroup of participants taking fisetinperipheral blood mononuclear cells

    Clinical validation of C₁₂FDG as a marker associated with senescence and osteoarthritic phenotypes

    Aging cell

More on C12FDG-positive PBMC percentage

TGF-β1/MMP-9 molecular pathways

mixedin cells1

1 study
  1. Fisetin is associated with TGF-β1/MMP-9 molecular pathways in cells (PHY1 phytosome in breast cancer).

    “pharmacodynamic studies confirmed the promoted cytotoxicity of PHY1 against breast cancer through modulating TGF-β1/MMP-9 molecular pathways of tumorigenesis.”

    CellsPHY1 phytosome in breast cancerphospholipid phytosome (PHY1, 1:1 molar ratio)

    Self-assembled fisetin-phospholipid complex: Fisetin-integrated phytosomes for effective delivery to breast cancer

    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

MTH1

no changein silico1

1 study
  1. Fisetin is associated with MTH1 in silico (molecular docking) (-11.4 kcal/mol binding affinity).

    “showed a considerable binding affinity for MTH1 (-11.4 kcal/mol)”

    In silicomolecular docking

    Fisetin induces apoptosis in human skin cancer cells through downregulating MTH1

    Journal of biomolecular structure & dynamics

More on MTH1

HCN2

mixedin silico1

1 study
  1. Fisetin is associated with HCN2 in silico (molecular docking) (binding energy -7.66 kcal/mol).

    “fisetin binds to the (5JON) HCN2 channel strongly with the binding energy of -7.66 kcal/mol”

    In silicomolecular docking

    Fisetin decreases the duration of ictal-like discharges in mouse hippocampal slices

    Journal of biological physics

More on HCN2

All 15

Has fisetin been tested in people?

13 of 24 about aging

Yes: 11 trials and 7 observational studies in people have been published, and 24 trials are registered.

Every condition in trials

  • COVID-19

    Phase 2Results posted3 trials

  • Frailty

    Phase 2Enrolling by invitation3 trials

  • Anatomic Stage II Breast Cancer AJCC v8

    Phase 2Recruiting2 trials

  • Anatomic Stage III Breast Cancer AJCC v8

    Phase 2Recruiting2 trials

  • Alzheimer's disease

    Phase 2Completed1 trial

  • Carpal tunnel syndrome

    Phase 2Results posted1 trial

All 24

Stopped

  • NCT04537299TerminatedCOVID-19

    The DSMB and NIA determined the study should be stopped due to futility.

  • NCT03325322SuspendedFrailty

    Due to lack of funding

Trial sponsors

Funding

8 grants since 2018

National Institute on Aging$3.4MUS Department of Veterans AffairsNational Institute of Allergy and Infectious Diseases$2.9M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Worm studies report lifespan extension with fisetin, and independent labs reproduce reduced inflammation in mice and oxidative stress in worms. Apoptosis increases in human cells but decreases in mice after ischemia–reperfusion injury; 10 registered trials concern aging. Some authors have company affiliations, and some papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that fisetin extends mouse lifespan and reduces senescence in human cells, while a mouse study reports increased frailty in rTg4510 mice. One group’s preprint trial reports reduced senescence-related gene expression in human blood cells. Nine registered trials concern aging; named funders include the National Institutes of Health, and an author is affiliated with Kewpie Corporation.

  3. Summary rewritten as its findings changed.

    As it read before

    A human cell study finds fisetin reduces SA-β-gal-positive cells, IL-1β and MCP-1, while increasing TP53 in H₂O₂-stimulated AD-MSCs. A mouse preprint reports reduced CD4+ T-cell pathogenic capacity; a review describes reductions in circulating SASP factors.

  4. Summary written from the findings.

Latest

Dec 2025: 9Jan 2026: 13Feb 2026: 3Mar 2026: 7Apr 2026: 10May 2026: 7Jun 2026: 5Jul 2026: 6Aug 2026: 6Sep 2026: 7Oct 2026: 4Nov 2026: 683 papers in 12 months
Annals of Allergy, Asthma & Immunology

Fisetin pilot trial hints at benefits in lung disease

At day 90, a lung gas-transfer measure rose by a median 1.36 mL/min/mmHg with fisetin versus 0.13 with placebo.At day 90, a lung gas-transfer measure rose by a median 1.36 mL/min/mmHg with fisetin versus 0.13 with placebo.

Randomized trial · 10 peopleFisetin

See all 428 papers on fisetin